{"id":"NCT00337285","sponsor":"New River Pharmaceuticals","briefTitle":"An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","officialTitle":"A Long-Term, Open-Label, and Single-Arm Study of NRP104 30 mg, 50 mg, or 70 mg Per Day in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2007-11","completion":"2008-06","firstPosted":"2006-06-15","resultsPosted":"2009-07-17","lastUpdate":"2012-08-20"},"enrollment":349,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder","Attention Deficit Disorders With Hyperactivity","Attention Deficit Hyperactivity Disorders"],"interventions":[{"type":"DRUG","name":"Vyvanse (lisdexamfetamine dimesylate), NRP104","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the long-term safety and efficacy of three NRP104 doses of 30 mg, 50 mg, or 70 mg, administered at the same time daily, in the treatment of adults with ADHD.","primaryOutcome":{"measure":"Change in ADHD-RS-IV Total Score From Baseline at Up to One Year","timeFrame":"up to one year","effectByArm":[{"arm":"Vyvanse","deltaMin":-24.8,"sd":11.7}],"pValues":[{"comp":"OG000","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":["21438796","22808446"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html"]},"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Upper respiratory tract infection","Insomnia","Headache","Dry mouth","Decreased appetite"]}}